ARS Pharmaceuticals/$SPRY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ARS Pharmaceuticals
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
- Ticker
- $SPRY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 198
- Headquarters
- San Diego, United States
- Website
- ars-pharma.com
SPRY Metrics
BasicAdvanced
$335M
-
-$2.18
0.97
-
Price and volume
Market cap
$335M
Beta
0.97
52-week high
$13.15
52-week low
$3.34
Average daily volume
1.5M
Financial strength
Current ratio
3.475
Quick ratio
3.146
Long term debt to equity
13.715
Total debt to equity
13.715
Interest coverage (TTM)
-28.76%
Profitability
EBITDA (TTM)
-214.646
Gross margin (TTM)
58.35%
Net profit margin (TTM)
-184.24%
Operating margin (TTM)
-184.96%
Effective tax rate (TTM)
0.04%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-48.02%
Return on equity (TTM)
-210.35%
Valuation
Price to revenue (TTM)
2.865
Price to book
26.78
Price to tangible book (TTM)
-241.44
Price to free cash flow (TTM)
-1.704
Free cash flow yield (TTM)
-58.69%
Free cash flow per share (TTM)
-1.984
Growth
Revenue change (TTM)
4.08%
Earnings per share change (TTM)
342.75%
3-year revenue growth (CAGR)
711.25%
3-year earnings per share growth (CAGR)
43.20%
What the Analysts think about SPRY
Analyst ratings (Buy, Hold, Sell) for ARS Pharmaceuticals stock.
Analyst projections of the future price of ARS Pharmaceuticals stock.
Bulls say / Bears say
U.S. adoption is building: Q2 neffy revenue reached $26.2 million, market share doubled year on year to 5%, and share in targeted accounts rose to 8%. More than 16,000 unique prescribers in the quarter suggests the focused sales strategy is reaching more clinicians. (ARS Pharmaceuticals)
ARS expects second-half cash selling, general and administrative and research costs of $100 million to $110 million, more than 40% below the first half, and sees a path to cash-flow breakeven by the end of 2027. If sales keep growing and the cost cuts land, the company could reduce its funding needs. (ARS Pharmaceuticals)
The franchise is expanding beyond the US: EURneffy 1 mg has EU approval, and neffy 2 mg launched in Canada in August through partner ALK. These launches give ARS additional markets to earn from without building each local commercial operation itself. (ARS Pharmaceuticals, ALK)
Payer access remains a hurdle: ARS reported no new commercial formulary additions or coverage decisions in the July cycle, and Q2 call materials showed that only 57% of commercial coverage was without prior authorisation. Limited easy access could slow new prescriptions and refills. (ARS Pharmaceuticals, The Motley Fool)
The company remains loss-making: Q2 net loss was $62.3 million, while cash and short-term investments fell from $201 million at the end of March to $143.8 million at the end of June. If sales growth or cost reductions fall short, ARS may need additional capital before reaching its stated breakeven target. (ARS Pharmaceuticals, ARS Pharmaceuticals)
Q2 gross margin was 62%, affected by reserves for short-dated product and manufacturing inefficiencies during the scale-up. If those pressures persist, sales will contribute less towards covering the company’s high operating costs. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
SPRY Financial Performance
Revenues and expenses
SPRY Earnings Performance
Company profitability
Upcoming events
No upcoming events
SPRY News
AllArticlesVideos
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Business Wire4 weeks ago
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY
Newsfile Corp4 weeks ago
SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Newsfile Corp4 weeks ago
Funds containing SPRY
Fund name | Fund size | $SPRY weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.